June 1 – 5, 2024

American Transplant Congress (ATC)

Philadelphia, PA

Kamada to exhibit at this year's meeting in Philadelphia!
Meet us at Booth #720 to discover more about how you can help your transplant patients

June 5, 2024 - 6 pm EST

Advanced Strategies for CMV Management after SOT

Live Online Event

Send your questions and interact with the specialists as they delve into the latest challenges and developments in this field.
For the full scientific program, panel member list and registration click here

Our Products

CMV infection remains one of the most common complications for solid organ transplant recipients1 and is still considered “the troll of transplantation."2

As an immune globulin, CYTOGAM® offers a complementary mechanism of action to antiviral agents, working outside the cell, thus adding enhanced protection against CMV post-transplant.3,4,5

References

  1. Haidar G, Boeckh M, Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis. 2020;221(S1):S23-S31. doi: 10.1093/infdis/jiz454
  2. Stern A, Papnicolaou GA. CMV prevention and treatment in transplantation: what’s new in 2019. Curr Infect Dis Rep. 2019; 21(11): 45. doi:10.1007/s11908-019-0699-0
  3. Grossi PA, Mohacsi P, Szabolcs Z, Potena L. Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016; 100: S1-S4
  4. Carbone J. The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100: S11-S18
  5. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin versus ganciclovir alone. Transplantation. 2001;72(10):1647-1652

Resources

Mechanism of Action Video

2024 CEoT Product Theater – Breakthroughs in Hyperimmune Therapy

2024 CEoT Product Theater – Anti-CMV Prophylaxis Strategies and Immune Response (in Lung Transplantation)

IDWeek 2023 UTSW Poster

Germer et al. 2016 Reprint Summary

Barten et al. 2022 Reprint Summary

HEPAGAM B is the only Hepatitis B Immune Globulin (HBIG):

  • Approved for post-transplant prophylaxis of hepatitis B in liver transplants.1
  • Proven to be safe and effective in preventing HBV recurrence following liver transplants2
  • With actual potency indicated on each vial to ensure high dosing accuracy1

References

  1. Kamada corporate presentation, September 2022
  2. Terrault NA, Kilic M, Karademir S, et al. HepaGam B after liver transplant in patients with hepatitis B virus. Available at: https://www.researchgate.net/publication/267792129_Orthotopic_HepaGam_B_After_Liver_Transplant_in_Patients_with_Hepatitis_B_Virus. Accessed July 27, 2022

Resources

Hepagam B

Varicella-zoster virus (VZV) infection remains a significant concern for transplant patients without sufficient VZV immunity1.

VARIZIG® is recommended as first-line treatment by leading guidelines for VZV post-exposure prophylaxis, to effectively reduce disease severity and complications after exposure of a high-risk individual to VZV1-3.

References

  1. Varicella Zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, 2019.
  2. The CDC updated Recommendations for Use of VARIZIG - United States, 2013.
  3. Red-Book: 2021–2024 Report of the Committee on Infectious Diseases.

Resources

Treatment Algorithm

Clinical Compendium

Research Collaborations

Kamada's Clinical Program aims to innovate in areas like solid organ transplantation. We specialize in hyperimmune plasma-derived therapies and seek to collaborate with the transplant community for clinical research.

If you are interested in sharing your clinical expertise, please contact our Director of Medical Affairs, Winston Ally at winstona@kamada.com

Important Safety Information Collapse
Important Safety Information Collapse

Please provide some basic information to access this content.